By Barrie Einarson | Trade Ideas | What Makes This Trade Great

---

Hey everyone — Barrie here with another edition of What Makes This Trade Great. Today I want to walk you through two biotech shorts that our AI flagged, and why sometimes the news catalyst is everything. To Subscribe to Trade Ideas: https://go.trade-ideas.com/SHQ
Use Promo Code BARRIE15 for 15% off

Let’s start with ABVX. This one was a fantastic AI-generated short — a little choppy early on, but look at it now.

Primary trade: ABVX

• Short entry: $82.87
• Move: −44%
• Catalyst: Phase 3 cancer drug trial — bad news

The short trigger was at $82.87. This is a bio company that came out with Phase 3 results on a cancer drug, and whatever they announced, the market absolutely hated it. We’re talking down 44%. It was already getting hit hard in pre-market, and then it just kept going. That’s the power of a hard news catalyst layered on top of an AI signal.

And ABVX wasn’t the only one. There was another bio name getting crushed today — CELC.

Secondary trade: CELC

• Entry: ~$97.64
• Recent print: ~$93.27
• Next support: ~$62

Different drug, different catalyst, same story. Bad news hit and the stock rolled over. Not as explosive as ABVX, but still a solid short. Entry was around $97.64, now trading near $93.27 — and if this thing keeps breaking down, the next major support level is somewhere around $62. There’s still plenty of potential move left.

The takeaway

Yes, the AI finds the setups. But when you add a genuine news catalyst on top — especially a failed clinical trial — these trades can run hard and fast. Keep an eye on the bio space, stay disciplined, and let the tools do the scanning for you.

See you in the next one.